Gastroenterology
Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
Yong Hwan Kwon, Seong Woo Jeon, Su Youn Nam, Dong Wook Lee, Ji Hey Park, Hui Jin Bae
Korean J Intern Med. 2023;38(4):493-503. Published online June 28, 2023
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this study, we evaluated the efficacy of a tegoprazan-based, nonbismuth-containing quadruple (concomitant) therapy for the primary eradication of Helicobacter pylori..
|